Abstract:The D1 dopamine receptor is linked to a variety of neuropsychiatric disorders and represents an attractive drug target for the enhancement of cognition in schizophrenia, Alzheimer disease, and other disorders. Positive allosteric modulators (PAMs), with their potential for greater selectivity and larger therapeutic windows, may represent a viable drug development strategy, as orthosteric D1 receptor agonists possess known clinical liabilities. We discovered two structurally distinct D1 receptor PAMs, MLS6585 and MLS1082, via a high-throughput screen of the NIH Molecular Libraries program small-molecule library. Both compounds potentiate dopamine-stimulated G protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies. Neither compound displayed any intrinsic agonist activity. Both compounds were also found to potentiate the efficacy of partial agonists. We tested maximally effective concentrations of each PAM in combination to determine if the compounds might act at separate or similar sites. In combination, MLS1082 + MLS6585 produced an additive potentiation of dopamine potency beyond that caused by either PAM alone for both β-arrestin recruitment and cAMP accumulation, suggesting diverse sites of action. In addition, MLS6585, but not MLS1082, had additive activity with the previously described D1 receptor PAM "Compound B," suggesting that MLS1082 and Compound B may share a common binding site. A point mutation (R130Q) in the D1 receptor was found to abrogate MLS1082 activity without affecting that of MLS6585, suggesting this residue may be involved in the binding/activity of MLS1082 but not that of MLS6585. Together, MLS1082 and MLS6585 may serve as important tool compounds for the characterization of diverse allosteric sites on the D1 receptor as well as the development of optimized lead compounds for therapeutic use.

Three-Dimensional Structure of Dopamine 3-Subtype Receptor with the Active Site Residues for the Binding of Dopamine

Dopaminergic Pharmacology Revealed by Structures of Human Dopamine D3 Receptor-G I Complexes

Molecular Modeling of the Three-Dimensional Structure of Dopamine 3 (D3) Subtype Receptor: Discovery of Novel and Potent D3 Ligands Through a Hybrid Pharmacophore- and Structure-Based Database Searching Approach.

Structures of the human dopamine D3 receptor-Gi complexes

Computational modeling toward understanding agonist binding on dopamine 3.

Homology modeling of Dopamine D2 receptor

Molecular Dynamics of Dopamine to Transmit Through Molecular Channels Within D3r

Dopamine 3 Receptor Homology Model and Its Application

Selectivity and Activation of Dopamine D3R from Molecular Dynamics

Structure-based drug design for dopamine D3 receptor.

Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist

Probing the Structural Determinants of the Central Region of Third Intracellular Loop of Human Dopamine D1‐class Receptor Subtypes (662.9)

Structural insights into the human D1 and D2 dopamine receptor signaling complexes

Ligand recognition and biased agonism of the D1 dopamine receptor

Structural genomics of the human dopamine receptor system

The Pivotal Distinction between Antagonists' and Agonists' Binding into Dopamine D4 Receptor—MD and FMO/PIEDA Studies

State transitions of coupled Gi-protein: Insights into internal water channel dynamics within dopamine receptor D3 from in silico submolecular analyses

Role of the Central Region of the Third Intracellular Loop of Human D1‐class Dopaminergic Receptors

Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor

Structural insights into G protein activation by D1 dopamine receptor

Design, Synthesis, and Evaluation of Indolebutylamines As a Novel Class of Selective Dopamine D3 Receptor Ligands.